RXT

(3R)-3-cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]propanenitrile

RXT as a free ligand exists in 1 entry. Examples include: 4U5J

Find related ligands: Stereoisomers Similar ligands Chemical Structure Search

View summary at Ligand Expo



Chemical Component Summary

Name(3R)-3-cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]propanenitrile
Identifiers(3R)-3-cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]propanenitrile
FormulaC17 H18 N6
Molecular Weight306.37
TypeNON-POLYMER
Isomeric SMILESN#CC[C@H](C1CCCC1)n1cc(cn1)-c1ncnc2[nH]ccc12
InChIInChI=1S/C17H18N6/c18-7-5-15(12-3-1-2-4-12)23-10-13(9-22-23)16-14-6-8-19-17(14)21-11-20-16/h6,8-12,15H,1-5H2,(H,19,20,21)/t15-/m1/s1
InChIKeyHFNKQEVNSGCOJV-OAHLLOKOSA-N

Chemical Details

Formal Charge0
Atom Count41
Chiral Atom Count1
Chiral AtomsCAV
Bond Count44
Aromatic Bond Count15
Leaving Atomsn/a

Drug Info: DrugBank

DrugBank IDDB08877 Different stereochemistry
NameRuxolitinib
Groupsapproved
DescriptionRuxolitinib is a janus-associated kinase inhibitor indicated to treat bone marrow cancer, specifically intermediate or high-risk myelofibrosis. FDA approved on November 16, 2011.
Synonyms
  • INCB018424
  • INCB424
SaltsRuxolitinib Phosphate
Brand Names
  • Jakafi
  • Jakavi
Affected OrganismHumans and other mammals
IndicationTreatment of intermediate or high-risk myelofibrosis, including primary myelofibrosis, post-polycythemia vera (post-PV) myelofibrosis and post-essential thrombocythemia (post-ET) myelofibrosis. [Lexicomp] Myeolofibrosis is the proliferation of abnormal bone marrow stem cells which cause fibrosis (the excessive formation of connective tissue).
PharmacologyThe mean half-maximal inhibitory concentration (IC50) for JAK 1 and JAK 2 are 2.8 nmol/L and 3.3 nmol/L respectively. After administration of ruxolitinib, a decrease in levels of phosphorylated STAT (marker for JAK activity) in a dose-dependent manner can be observed. Pharmacodynamic resistance has not been observed.
Mechanism of actionRuxolitinib is a kinase inhibitor that is selective for the Janus Associated Kinases (JAK) 1 and 2. These kinases are responsible for the mediation of cytokine and growth factor signalling which in turn effect immune function and hematopoiesis. The signalling process involves signal transducers and transcription activators (STAT) which modulate gene expression. Patients with myelofibrosis have abnormal JAK1 and JAK2 activity thus ruxolitinib works to regulate this.
Route of administrationOral
Categories
  • Antineoplastic Agents
  • Antineoplastic and Immunomodulating Agents
  • Azoles
  • Cytochrome P-450 CYP3A4 Substrates
  • Heterocyclic Compounds
ATC-CodeL01XE18
AHFS-Code10:00
CAS number941678-49-5
Drug Info/Drug Targets: DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Knox C, Law V, Jewison T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS. Nucleic Acids Res. 2011 Jan; 39 (Database issue):D1035-41. | PMID:21059682